UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug
Samsung BioLogics said it has signed a deal with U.S. biotech firm CytoDyn ...
by Jeong Sae-im
|
2019-05-31 14:59
라인
Announcement of Invossa license revocation was ‘procedural breach’: Kolon
The government’s recent announcement that it would nullify the license of I...
by Jeong Sae-im
|
2019-05-30 13:28
라인
Medytox suspected of GMP violation filed at anti-corruption commission
Medytox, the Korean botulinum toxin maker, is suspected of breaching Good M...
by Jeong Sae-im
|
2019-05-27 15:52
라인
‘Shareholders can surely win lawsuit against Kolon’
Law firm Hankyul is pursuing a lawsuit against Kolon Life Science and Kolon...
by Jeong Sae-im
|
2019-05-24 19:34
라인
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients
More than 50 days have passed since the Ministry of Food and Drug Safety (M...
by Jeong Sae-im
|
2019-05-22 11:59
라인
Legislator, activists call for revoking Invossa license, conducting probes
A lawmaker and civic groups urged the government to nullify the license of ...
by Jeong Sae-im
|
2019-05-21 16:03
라인
[Reporter’s Notebook] ‘Wanna know what’s going on with MSD Korea?’
“Is there any trouble between Korea Biomedical Review and MSD Korea?”People...
by Jeong Sae-im
|
2019-05-21 11:44
라인
Kolon to follow 3,700 Invossa-treated patients for 15 years
Kolon Life Science said it would conduct a long-term follow-up study on ove...
by Jeong Sae-im
|
2019-05-17 15:38
라인
Will Celltrion CEO’s bet on ‘bio valley’ pay off?
“It’s been 19 years since I started this business. The first decade was a t...
by Jeong Sae-im
|
2019-05-17 13:21
라인
CHA Biotech’s operating income plunges 92% in Q1
CHA Biotech said in a public filing on Wednesday that it recorded 124.4 bil...
by Jeong Sae-im
|
2019-05-16 13:41
라인
KangStem Biotech completes stem cell drug plant
“KangStem Biotech aims to become a leader in the global stem cell therapy m...
by Jeong Sae-im
|
2019-05-16 11:27
라인
Samsung BioLogics in tight spot amid probe, shareholders’ lawsuit
Prosecutors are speeding up the probe into Samsung BioLogics for alleged ac...
by Jeong Sae-im
|
2019-05-14 14:10
라인
‘MSD Korea’s foreign exec got drunk, sexually harassed female worker’
A foreign executive at MSD Korea not only sexually harassed a female employ...
by Jeong Sae-im
|
2019-05-14 11:53
라인
Celltrion’s operating income down 33% in Q1
Biopharmaceutical firm Celltrion said it suffered a 32.9 percent decline in...
by Jeong Sae-im
|
2019-05-09 15:26
라인
If Invossa license gets revoked, Kolon should return $13 million to Mundipharma
The licensing deal between Kolon Life Science and Mundipharma for osteoarth...
by Jeong Sae-im
|
2019-05-08 15:33
라인
Mobile healthcare firm Noom raises $58 million for biz expansion
Noom, a New York-based mobile healthcare company, said it has attracted $58...
by Jeong Sae-im
|
2019-05-08 15:23
라인
Inspection will clear all suspicions over Invossa: TissueGene
Kolon TissueGene finally broke silence amid a growing suspicion that it mig...
by Jeong Sae-im
|
2019-05-08 14:32
라인
Kolon might have covered up Invossa mislabeling for 2 years
Kolon TissueGene said in a public filing that it notified its parent compan...
by Jeong Sae-im
|
2019-05-07 15:55
라인
[Exclusive] MSD workers appalled by executive’s remarks on childcare leave
MSD Korea recently revised a policy to allow employees on child care leave ...
by Jeong Sae-im
|
2019-05-07 12:08
라인
Civic group files complaint against Kolon, regulator
A non-government consumer group has complained with the prosecution against...
by Jeong Sae-im
|
2019-04-30 14:59
-
이전
11
12
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top